What is a potential consequence of using erythropoiesis-stimulating agents (ESAs)?

The use of erythropoiesis-stimulating agents (ESAs) has been associated with an increased risk of developing thromboembolic events, including stroke. ESAs stimulate the production of red blood cells, which can lead to an increased hemoglobin level and heightened blood viscosity. This elevated viscosity can contribute to the formation of blood clots, thereby increasing the risk of complications such as stroke, myocardial infarction, or venous thromboembolism.

In clinical practice, monitoring for these potential risks is crucial, especially in patients with pre-existing cardiovascular conditions. By understanding the relationship between ESAs and their effects on blood viscosity and clot formation, healthcare providers can better manage patient treatment plans and minimize adverse outcomes.

While decreased blood pressure, higher likelihood of infections, and improved appetite may be concerns in different contexts or treatments, they do not directly correlate with the use of ESAs in the same manner as the risk of stroke does.